Blueprint Medicines
160 articles about Blueprint Medicines
-
Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
7/24/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines Agency's Committee for Medicin
-
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
7/23/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday , July 30, 2020 to report its second quarter 2020 financial results and provide
-
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
7/14/2020
Blueprint Medicines and Genentech, a member of the Roche Group, to co-commercialize pralsetinib and equally share profits in the U.S.
-
Shares of Blueprint Medicines are climbing in premarket trading after the company inked a collaboration worth more than $1 billion with Genentech to develop a treatment for cancers driven by oncogenic RET alteration.
-
Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
7/1/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pralsetinib for the treatment of patients with advanced or metast
-
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
6/29/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that The Lancet Oncology published data from the NAVIGATOR clinical trial showing an unprecedented overall survival (OS) rate and a well-tolerated safety profile for AYVAKIT™
-
Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
6/6/2020
Updated PIONEER trial data in patients with indolent SM showed response rate of 60% for avapritinib versus 0% for placebo at 24 weeks, with response defined as ≥30% reduction in total symptom score
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 03, 2020
6/3/2020
Blueprint Medicines Corporation announced that, effective on June 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 49,493 shares of its common stock and an aggregate of 24,745 restricted stock units to four new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
5/29/2020
-- Registrational data in RET fusion-positive NSCLC show 61% ORR in patients previously treated with platinum-based chemotherapy and 73% ORR in treatment-naïve patients -- -- 12% complete response rate in patients with treatment-naïve RET fusion-positive NSCLC -- -- Median DOR not reached across lines of therapy in RET fusion-positive NSCLC, with 6-month DOR of 86% -- -- NDA accepted by FDA and MAA validated by EMA for pralsetinib in RET fusion-positive NSCLC --
-
Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
5/26/2020
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers.
-
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
5/15/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib for the treatment of adults
-
Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
5/14/2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis.
-
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
-
Blueprint Medicines Reports First Quarter 2020 Financial Results
5/6/2020
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported financial results and provided a business update for the first quarter ended March 31, 2020.
-
Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020
4/29/2020
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 6, 2020 to report its first quarter 2020 financial results and provide a corporate update.
-
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
4/28/2020
VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis
3/16/2020
Blueprint Medicines Corporation today announced updated results from the Phase 2 pioneer trial.
-
Blueprint Medicines to Present at Upcoming Investor Conferences - Feb. 19, 2020
2/19/2020
Blueprint Medicines Corporation announced its participation in fireside chats at the following upcoming investor conferences
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
2/6/2020
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update.